Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Butler

Ophthalmology Dallas, TX Medical Doctor

NPI 1447403837 CMS profile 337586

10740 N Central Expy, Suite 300, Dallas, TX 75231

Open in the dashboard

General payments

$11,718

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$41,038 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Michelle Butler of Dallas, TX is reported in the CMS Open Payments database as having received $11,718 across 146 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $41,038 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $655 21
2024 General $822 23
2023 General $497 23
2022 General $638 27
2021 General $178 9
2020 General $8,127 22
2019 General $800 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Butler
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Michelle Butler were reported at $655. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Michelle Butler Ophthalmology median Middle half National median
2019 $800 $258 $104–$655 $163
2020 $8,127 $126 $45–$321 $114
2021 $178 $205 $76–$534 $132
2022 $638 $266 $100–$678 $149
2023 $497 $308 $117–$745 $160
2024 $822 $340 $127–$846 $164
2025 $655 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. New World Medical,Inc. $5,036 3 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $2,019 5 payments
  3. Allergan Inc. $1,719 31 payments
  4. AbbVie, Inc. $1,325 55 payments
  5. Glaukos Corporation $357 4 payments
  6. Alcon Vision LLC $313 13 payments
  7. Aerie Pharmaceuticals, Inc. $259 9 payments
  8. Horizon Therapeutics plc $217 5 payments
  9. Amgen Inc. $116 3 payments
  10. Bausch & Lomb Americas Inc. $92 4 payments
  11. Other $265 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,730 3 payments
  2. Food and Beverage $3,446 140 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $400 1 payment
  4. Travel and Lodging $97 1 payment
  5. Gift $45 1 payment
Products named General payments · program years 2019–2025
  1. Ahmed Glaucoma Valve $5,036 3 payments
  2. Kahook Dual Blade $5,036 3 payments
  3. VYZULTA $2,111 9 payments
  4. XEN GLAUCOMA TREATMENT SYSTEM $638 24 payments
  5. COMBIGAN $454 5 payments
  6. LUMIGAN Ophthalmology $440 8 payments
  7. DURYSTA $376 13 payments
  8. iDose $311 2 payments
  9. LUMIGAN Eye Care $275 11 payments
  10. TEPEZZA $217 5 payments
  11. Other $1,796 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

7,528

Median for Ophthalmology: 891

Drug cost

$576,488

Median for Ophthalmology: $68,233

Branded share of claims

31%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rhopressa Netarsudil Mesylate Brand 161 $66,773
Lumigan Bimatoprost Brand 130 $65,045
Combigan Brimonidine Tartrate/Timolol Brand 141 $58,459
Vyzulta Latanoprostene Bunod Brand 103 $47,312
Rocklatan Netarsudil Mesylat/Latanoprost Brand 76 $43,787
Restasis Cyclosporine Brand 33 $38,605
Alphagan P Brimonidine Tartrate Brand 90 $35,864
Prednisolone Acetate Generic 515 $24,618
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 158 $24,146
Brimonidine Tartrate Generic 691 $23,778

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$388,184

Medicare's payments for the services billed

Medicare patients

1,065

Average age 77

Services billed

5,645

616 women, 449 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 28%
Diabetes 25%
Chronic kidney disease 22%
Atrial fibrillation 17%
Depression 17%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $142
$142 — —
LUMIGAN
  • AbbVie, Inc. $95
$95 130 —
Rocklatan
  • Alcon Vision LLC $44
$44 76 —
TEPEZZA
  • Amgen Inc. $41
$41 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $18
$18 103 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record